S'abonner

A genome-wide association study to identify genetic determinants of atopy in subjects from the United Kingdom - 10/08/11

Doi : 10.1016/j.jaci.2010.10.006 
Yize I. Wan, BMedSci a, , David P. Strachan, MD b, David M. Evans, PhD c, John Henderson, MD d, Tricia McKeever, PhD e, John W. Holloway, BSc, PhD f, Ian P. Hall, DM, FRCP a, Ian Sayers, BSc, PhD a
a Division of Therapeutics and Molecular Medicine, Nottingham Respiratory Biomedical Research Unit, University Hospital of Nottingham, Nottingham, United Kingdom 
b Division of Community Health Sciences, St Georges’ Medical School, London, United Kingdom 
c Department of Social Medicine, University of Bristol, Bristol, United Kingdom 
d Department of Community-Based Medicine, University of Bristol, Bristol, United Kingdom 
e Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom 
f Division of Human Genetics and Division of Infection, Inflammation and Immunity, University of Southampton School of Medicine, Southampton, United Kingdom 

Reprint requests: Yize I Wan, BMedSci, Division of Therapeutics and Molecular Medicine, University Hospital of Nottingham, Nottingham, NG7 2UH, United Kingdom.

Abstract

Background

A genetic component in the development of atopy has been identified. However, numerous heritability models have been proposed with inconsistent replication of susceptibility loci and genes.

Objective

We sought to use a genome-wide association study approach to examine genetic susceptibility to atopy, which was defined as increased specific IgE levels, positive skin prick test (SPT) responses, or both, within a large discovery cohort and 3 additional white populations.

Methods

Single nucleotide polymorphisms (SNPs) across the genome were tested for association with increased specific IgE levels (≥0.35 kUA/L) in the British 1958 Birth Cohort (1083 cases and 2770 control subjects; Illumina 550K Array) to 1 or more allergens, including house dust mite (Der p 1), mixed grass, or cat fur. Independent replication of identified loci (P ≤ .05) was assessed in 3 case-control cohorts from the United Kingdom (n = 3225). Combined analyses of data for top signals across cohorts were conducted for atopic phenotypes: increased specific IgE levels (1378 cases and 3151 control subjects) and positive SPT responses (1058 cases and 2167 control subjects).

Results

A single SNP on chromosome 13q14 met genome-wide significance (P = 2.15 × 10−9), and a further 6 loci (4.50 × 10−7P ≤ 5.00 × 10−5) showed weaker evidence for association with increased specific IgE levels in the British 1958 Birth Cohort. However, no SNPs studied showed consistent association with atopy defined by increased specific IgE levels, positive SPT responses, or both in all study cohorts.

Conclusions

Seven putative atopy loci were identified using a genome-wide association study approach but showed limited replication across several white populations. This study suggests that large-scale analyses with results from multiple populations will be needed to reliably identify key genetic factors underlying atopy predisposition.

Le texte complet de cet article est disponible en PDF.

Key Words : Atopy, specific IgE, skin prick test, genome-wide association study, British 1958 Birth Cohort

Abbreviations used : ALSPAC, FNDC3A, GWAS, SNP, SPT


Plan


 We acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection, funded by Medical Research Council grant G0000934 and Wellcome Trust grant 068545/Z/02 (www.b58cgene.sgul.ac.uk/). This analysis uses genotype data deposited by the Wellcome Trust Sanger Institute and by the Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, which is funded by the Juvenile Diabetes Research Foundation International, the Wellcome Trust, and the National Institute for Health Research Cambridge Biomedical Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award (079895). The British 1958 Birth Cohort genotypes deposited by DIL were generated by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Allergy and Infectious Diseases (NIAID), the National Human Genome Research Institute (NHGRI), the National Institute of Child Health and Human Development (NICHD), and the Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children Cohort. The Nottingham Gedling cohort collection was funded by Asthma UK and the British Lung Foundation. The Southampton cohort is supported by Asthma, Allergy, and Inflammation Research (AAIR).
 Disclosure of potential conflict of interest: J. Henderson receives research support from the Medical Research Council (UK). I. P. Hall receives research support from Asthma UK. The rest of the authors have declared that they have no conflict of interest.


© 2010  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 127 - N° 1

P. 223 - janvier 2011 Retour au numéro
Article précédent Article précédent
  • The role of penicillin in benign skin rashes in childhood: A prospective study based on drug rechallenge
  • Jean-Christoph Caubet, Laurent Kaiser, Barbara Lemaître, Benoît Fellay, Alain Gervaix, Philippe A. Eigenmann
| Article suivant Article suivant
  • Calcitonin gene-related peptide– and vascular endothelial growth factor–positive inflammatory cells in late-phase allergic skin reactions in atopic subjects
  • A. Barry Kay

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.